CSL to Settle for $64 Million Suits Involving Plasma Therapy Pricing

CSL Ltd. said Oct. 7 it will pay $64 million to settle federal multidistrict litigation in the U.S. District Court for the Northern District of Illinois alleging that it took part in a price-fixing scheme for blood plasma products (In Re Plasma-Derivative Protein Therapies Antitrust Litig.).

The Northern District of Illinois must approve the settlement, CSL said. The co-defendant industry trade group the Plasma Protein Therapeutics Association (PPTA) also was part of the settlement agreement.

CSL Chief Executive Officer Paul Perreault said in a statement, “While we continue to strongly reject any allegation of wrongdoing, we have negotiated ...